Clinical Trial Update: Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1) [Phase 3]

View source ↗

Summary

Phase 3 study ODYSSEY CHOICE 1 evaluated the efficacy and safety of an every-four-weeks dosing regimen of alirocumab (Praluent) in patients with primary hyperch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Praluent (alirocumab) (alirocumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2017-03-21